Latest & greatest articles for aspirin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on aspirin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on aspirin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Aspirin

Acetylsalicylic acid (ASA) more commonly known as aspirin is a painkiller that has a wide range of uses. It is frequently used to treat fever, mild pain, tooth aches, headaches and muscle aches. Aspirin is a nonsteroidal anti-inflammatory drug (NSAID) and can be used in the management of conditions such as heart attack, arthritis, blood clots and stroke. Aspirin, has been used for thousands of years, initially extracted from the leaves of willow trees.

Aspirin works in much the same way as other NSAIDs but has additional properties, such as antiplatelet activity which can make it additionally useful. More recently aspirin has been linked with cancer prevention. But the potential benefits of aspirin need to be weighed against the potential side effects, which includes gastrointestinal bleeding and Reye’s syndrome. It should be noted that aspirin should not be used in people who are allergic to drugs such as ibuprofen or a more generalized intolerance to NSAIDs. It should also be used cautiously in asthmatics and/or those with bronchospasm associated with NSAID use.

Research evidence, clinical trials and guidelines on Aspirin

The Trip Database has an extensive collection of articles on aspirin ranging from clinical trials, systematic reviews, clinical guidelines and case reports. These can be found via searching the site.

Top results for aspirin

501. Use of Aspirin, Other Nonsteroidal Anti-Inflammatory Drugs, and Acetaminophen and Postmenopausal Breast Cancer Incidence (Full text)

Use of Aspirin, Other Nonsteroidal Anti-Inflammatory Drugs, and Acetaminophen and Postmenopausal Breast Cancer Incidence The associations between use of aspirin, other nonsteroidal anti-inflammatory drugs (NSAIDs), and acetaminophen and breast cancer incidence in postmenopausal women are uncertain. We examined these associations with breast cancer, both overall and by molecular subtype.We observed 84,602 postmenopausal women, free of cancer in 1980, until June 2008 and prospectively collected (...) data on analgesic use, reproductive history, and other lifestyle factors using biennial questionnaires. Proportional hazards models were used to estimate multivariable relative risks (RRs) and 95% CIs.We documented 4,734 cases of incident invasive breast cancer. Compared with nonuse of aspirin, multivariable RRs of regular aspirin use (≥ two tablets per week) for more than 20 years were 0.91 for overall breast cancer (95% CI, 0.81 to 1.01; P(trend) = 0.16), 0.90 for estrogen receptor (ER) -positive

2012 EvidenceUpdates PubMed abstract

502. Fluorouracil/salicylic acid (Actikerall®)

Fluorouracil/salicylic acid (Actikerall®) Fluorouracil/salicylic acid (Actikerall®) Fluorouracil/salicylic acid (Actikerall®) All Wales Medicines Strategy Group (AWMSG) Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation All Wales Medicines Strategy Group (AWMSG). Fluorouracil/salicylic acid (Actikerall®) Penarth: All Wales Therapeutics and Toxicology Centre (AWTTC (...) ), secretariat of the All Wales Medicines Strategy Group (AWMSG). AWMSG Secretariat Assessment Report Advice No.1012. 2012 Authors' conclusions Fluorouracil/salicylic acid (Actikerall®) is recommended as an option for use within NHS Wales for the topical treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (grade I/II) in immunocompetent adult patients. Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Drug Combinations; Fluorouracil; Keratosis

2012 Health Technology Assessment (HTA) Database.

503. Purine analogues compared with mesalamine or 5-ASA for the prevention of postoperative recurrence in Crohn's disease: a meta-analysis (Abstract)

Purine analogues compared with mesalamine or 5-ASA for the prevention of postoperative recurrence in Crohn's disease: a meta-analysis Objective:  To use a meta-analysis approach to evaluate the efficacy and safety of purine analogues, azathioprine (AZA) and 6-mercaptopurine (6-MP), in the prevention of postoperative recurrence of Crohn's disease (CD), as compared with mesalamine or 5-aminosalicylic acid (5-ASA). Methods:  The Pubmed, Cochrane Library, and Embase literature databases were (...) searched for relevant studies with the key words "azathioprine", "6-mercaptopurine", "purine analogue", "mesalamine", or "5-ASA". The efficacy and safety of purine analogues in the retrieved randomized controlled trials (RCTs) were evaluated with RevMan 5.0.25 (The Cochrane Collaboration, Oxford, England) and STATA 12.0 (Stata Corporation, College Station, TX, USA). The outcome measures of AZA and 6-MP, compared to mesalamine and 5-ASA (control arms), were: clinical recurrence, endoscopic recurrence

2012 EvidenceUpdates

504. Warfarin and aspirin did not differ for death or stroke in heart failure and sinus rhythm. (Abstract)

Warfarin and aspirin did not differ for death or stroke in heart failure and sinus rhythm. 22910961 2012 10 19 2012 08 22 1539-3704 157 4 2012 Aug 21 Annals of internal medicine Ann. Intern. Med. ACP Journal Club: warfarin and aspirin did not differ for death or stroke in heart failure and sinus rhythm. JC2-7 10.7326/0003-4819-157-4-201208210-02007 Ahmad Tariq T Duke University School of Medicine, Durham, North Carolina, USA. Felker G Michael GM eng Comment Journal Article United States Ann

2012 Annals of Internal Medicine

505. Is there an association between aspirin dosing and cardiac and bleeding events after treatment of acute coronary syndrome? A systematic review of the literature. (Abstract)

Is there an association between aspirin dosing and cardiac and bleeding events after treatment of acute coronary syndrome? A systematic review of the literature. Current acetylsalicylic acid (ASA) dosing algorithms for the prevention of secondary thrombotic events in acute coronary syndrome (ACS) patients are inconsistent and lack sufficient data support.We performed a systematic review of the literature for studies that assessed clinical outcomes in patients with ACS following coronary stent (...) insertion (SI) or medical treatment (MT). Acetylsalicylic acid dosing was stratified into low- (<160 mg) and high- (≥ 160 mg) dose categories. Outcomes were assessed at 1, 6, and 12 months and included major bleeding, myocardial infarction, and all-cause death. A random-effects meta-analysis was used to estimate the value of the mean for each outcome variable.Of 12,472 publications identified, 136 studies with 289,330 patients were analyzed. In the 1-month SI analysis, proportions of patients (95% CI

2012 American heart journal

506. Aspirin for the primary prevention of cardiovascular diseases. (Full text)

Aspirin for the primary prevention of cardiovascular diseases. 22669555 2012 12 07 2018 11 13 1970-9366 7 4 2012 Aug Internal and emergency medicine Intern Emerg Med Aspirin for the primary prevention of cardiovascular diseases. 375-9 10.1007/s11739-012-0791-z Tagliabue Ludovica L Scuola di Specializzazione in Igiene e Medicina Preventiva, Università degli Studi di Milano, Milan, Italy. ludovica.tagliabue@gmail.com Dipaola Franca F Perego Francesca F Podda Gian Marco GM Gruppo di Autoformazione (...) Metodologica (GrAM) eng Journal Article Meta-Analysis Research Support, Non-U.S. Gov't 2012 06 06 Italy Intern Emerg Med 101263418 1828-0447 0 Platelet Aggregation Inhibitors R16CO5Y76E Aspirin IM Aspirin therapeutic use Cardiovascular Diseases mortality prevention & control Confidence Intervals Humans Platelet Aggregation Inhibitors therapeutic use Primary Prevention methods Risk Assessment methods 2012 03 23 2012 05 05 2012 6 7 6 0 2012 6 7 6 0 2012 12 12 6 0 ppublish 22669555 10.1007/s11739-012-0791-z

2012 Internal and emergency medicine PubMed abstract

507. Review: Daily aspirin reduces short-term risk for cancer and cancer mortality. (Abstract)

Review: Daily aspirin reduces short-term risk for cancer and cancer mortality. 22801694 2012 09 24 2012 07 17 1539-3704 157 2 2012 Jul 17 Annals of internal medicine Ann. Intern. Med. ACP Journal Club. Review: daily aspirin reduces short-term risk for cancer and cancer mortality. JC2-2, JC2-3 10.7326/0003-4819-157-2-201207170-02002 Diehl Andrew K AK eng Comment Journal Article United States Ann Intern Med 0372351 0003-4819 Lancet. 2012 Apr 28;379(9826):1602-12 22440946 2012 7 18 6 0 2012 7 18 6

2012 Annals of Internal Medicine

508. ACP Journal Club. Individual-patient meta-analysis: daily aspirin reduces risk for incident cancer with distant metastasis. (Abstract)

ACP Journal Club. Individual-patient meta-analysis: daily aspirin reduces risk for incident cancer with distant metastasis. 22801695 2012 09 24 2012 07 17 1539-3704 157 2 2012 Jul 17 Annals of internal medicine Ann. Intern. Med. ACP Journal Club. Individual-patient meta-analysis: daily aspirin reduces risk for incident cancer with distant metastasis. JC2-2, JC2-3 10.7326/0003-4819-157-2-201207170-02003 Diehl Andrew K AK eng Comment Journal Article United States Ann Intern Med 0372351 0003-4819

2012 Annals of internal medicine

509. Review: Aspirin does not reduce CHD or cancer mortality but increases bleeding. (Abstract)

Review: Aspirin does not reduce CHD or cancer mortality but increases bleeding. 22711104 2012 08 20 2013 04 17 1539-3704 156 12 2012 Jun 19 Annals of internal medicine Ann. Intern. Med. ACP Journal Club. Review: Aspirin does not reduce CHD or cancer mortality but increases bleeding. JC6-3 10.7326/0003-4819-156-12-201206190-02003 Rembold Christopher M CM University of Virginia, Charlottesville, Virginia, USA. eng Comment Journal Article United States Ann Intern Med 0372351 0003-4819 Arch Intern

2012 Annals of Internal Medicine

510. Association of aspirin use with major bleeding in patients with and without diabetes. (Full text)

Association of aspirin use with major bleeding in patients with and without diabetes. The benefit of aspirin for the primary prevention of cardiovascular events is relatively small for individuals with and without diabetes. This benefit could easily be offset by the risk of hemorrhage.To determine the incidence of major gastrointestinal and intracranial bleeding episodes in individuals with and without diabetes taking aspirin.A population-based cohort study, using administrative data from 4.1 (...) million citizens in 12 local health authorities in Puglia, Italy. Individuals with new prescriptions for low-dose aspirin (≤300 mg) were identified during the index period from January 1, 2003, to December 31, 2008, and were propensity-matched on a 1-to-1 basis with individuals who did not take aspirin during this period.Hospitalizations for major gastrointestinal bleeding or cerebral hemorrhage occurring after the initiation of antiplatelet therapy.There were 186,425 individuals being treated

2012 JAMA PubMed abstract

511. Aspirin and cancer risk: a quantitative review to 2011. (Full text)

Aspirin and cancer risk: a quantitative review to 2011. Aspirin has been associated to a reduced risk of colorectal and possibly of a few other common cancers.To provide an up-to-date quantification of this association, we conducted a meta-analysis of all observational studies on aspirin and 12 selected cancer sites published up to September 2011.Regular aspirin is associated with a statistically significant reduced risk of colorectal cancer [summary relative risk (RR) from random effects (...) % CI = 0.85-0.96), while lung cancer was significantly reduced in case-control studies (0.73, 95% CI = 0.55-0.98) but not in cohort ones (RR = 0.98, 95% CI = 0.92-1.05). No meaningful overall associations were observed for cancers of the pancreas, endometrium, ovary, bladder, and kidney.Observational studies indicate a beneficial role of aspirin on colorectal and other digestive tract cancers; modest risk reductions were also observed for breast and prostate cancer. Results are, however

2012 Annals of oncology : official journal of the European Society for Medical Oncology / ESMO PubMed abstract

512. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials

Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2012 DARE.

513. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials

Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2012 DARE.

514. Esomeprazole Alone Compared with Esomeprazole Plus Aspirin for the Treatment of Aspirin-Related Peptic Ulcers (Abstract)

Esomeprazole Alone Compared with Esomeprazole Plus Aspirin for the Treatment of Aspirin-Related Peptic Ulcers Aspirin-related peptic ulcers are a common disorder. However, whether or not aspirin should be continued during treatment for aspirin-related ulcers remains unclear.To compare esomeprazole alone with esomeprazole plus aspirin in the treatment of aspirin-related peptic ulcers and to investigate the independent factors associated with the failure of ulcer healing.From January 2008 to July (...) 2011, patients with aspirin-related peptic ulcers were randomized to receive esomeprazole (40 mg per day) alone or esomeprazole (40 mg per day) plus aspirin (100 mg per day) for 8 weeks. The subjects with Helicobacter pylori infection were treated with standard triple therapy. Follow-up endoscopy was carried out at the end of the 8th week. The primary end point was the healing of peptic ulcers.In all, 178 patients (89 receiving esomeprazole alone and 89 receiving esomeprazole plus aspirin) were

2012 EvidenceUpdates Controlled trial quality: predicted high

515. Aspirin is not recommended for women undergoing IVF. (Full text)

Aspirin is not recommended for women undergoing IVF. 22258759 2013 05 16 2018 12 01 1460-2369 18 3 2012 May-Jun Human reproduction update Hum. Reprod. Update Aspirin is not recommended for women undergoing IVF. 233 10.1093/humupd/dmr049 Siristatidis Charalampos S CS 3rd Department of Obstetrics & Gynecology, University of Athens, Assisted Reproduction Unit, Attikon University Hospital, Rimini 1, Chaidari, Athens, 12462, Greece. harrysiri@yahoo.gr Dodd S R SR Drakeley A J AJ eng Journal Article (...) Meta-Analysis Review 2012 01 18 England Hum Reprod Update 9507614 1355-4786 0 Fertility Agents, Female R16CO5Y76E Aspirin IM Aspirin administration & dosage Female Fertility Agents, Female administration & dosage Fertilization in Vitro Humans Live Birth epidemiology Pregnancy Pregnancy Rate Randomized Controlled Trials as Topic 2012 1 20 6 0 2012 1 20 6 0 2013 5 17 6 0 ppublish 22258759 dmr049 10.1093/humupd/dmr049

2012 Human reproduction update PubMed abstract

516. Aspirin and prevention-who knows best?

Aspirin and prevention-who knows best? Aspirin and prevention-who knows best? | TrustTheEvidence.net Syndicate Discover the truth behind the research findings that affect everyday healthcare. » » Links Tags HONcode Certified This site complies with the for trustworthy health information: . Aspirin and prevention-who knows best? Ami Banerjee Last edited 30th March 2012 As the UK descends into hysteria around petrol and pasties, I have been reflecting for the last week on Peter Rothwell’s recent (...) Lancet papers about cancer prevention and the role of aspirin. Basically, daily low-dose aspirin not only , but also the . Aspirin is in the drug cabinet of hospital wards and GP surgeries, but we continue to discover more about its roles in medicine. As new evidence appears on the horizon, the information and guidelines for practising doctors and their patients still continues to change. There are inevitably time delays in how quickly new information filters through healthcare settings and broader

2012 TrustTheEvidence

517. Are we ready to recommend aspirin for the prevention of cancer? (Full text)

Are we ready to recommend aspirin for the prevention of cancer? 22440945 2012 05 14 2018 12 01 1474-547X 379 9826 2012 04 28 Lancet (London, England) Lancet Are we ready to recommend aspirin for cancer prevention? 1569-71 10.1016/S0140-6736(11)61654-1 Chan Andrew T AT Division of Gastroenterology, Massachusetts General Hospital, Harvard Medical School, Boston, USA. Cook Nancy R NR eng R01 CA047988 CA NCI NIH HHS United States R01 CA137178 CA NCI NIH HHS United States Journal Article Comment (...) 2012 03 21 England Lancet 2985213R 0140-6736 0 Antineoplastic Agents 0 Platelet Aggregation Inhibitors R16CO5Y76E Aspirin AIM IM Lancet. 2012 Apr 28;379(9826):1602-12 22440946 Antineoplastic Agents therapeutic use Aspirin therapeutic use Female Humans Male Neoplasms epidemiology prevention & control Platelet Aggregation Inhibitors therapeutic use 2012 3 24 6 0 2012 3 24 6 0 2012 5 15 6 0 ppublish 22440945 S0140-6736(11)61654-1 10.1016/S0140-6736(11)61654-1 PMC3415297 NIHMS393616 Ann Intern Med

2012 Lancet PubMed abstract

518. Aspirin, Nonsteroidal Anti-inflammatory Drug Use, and Risk for Crohn Disease and Ulcerative Colitis: A Cohort Study. (Full text)

Aspirin, Nonsteroidal Anti-inflammatory Drug Use, and Risk for Crohn Disease and Ulcerative Colitis: A Cohort Study. Aspirin and nonsteroidal anti-inflammatory drugs (NSAIDs) are anti-inflammatory but have been linked in some studies to Crohn disease (CD) and ulcerative colitis (UC).To assess the association between aspirin and NSAID use and incident CD and UC.Prospective cohort study.Nurses' Health Study I.76,795 U.S. women who provided biennially updated data about aspirin and NSAID (...) use.Incident CD and UC between 1990 and 2008 (outcome) and NSAID and aspirin use (exposure).123 incident cases of CD and 117 cases of UC occurred over 18 years and 1,295,317 person-years of follow-up. Compared with nonusers, women who used NSAIDs at least 15 days per month seemed to have increased risk for both CD (absolute difference in age-adjusted incidence, 6 cases per 100,000 person-years [95% CI, 0 to 13]; multivariate hazard ratio, 1.59 [CI, 0.99 to 2.56]) and UC (absolute difference, 7 cases per

2012 Annals of Internal Medicine PubMed abstract

519. Aspirin for the prevention of cardiovascular events in patients without clinical cardiovascular disease: a meta-analysis of randomized trials

Aspirin for the prevention of cardiovascular events in patients without clinical cardiovascular disease: a meta-analysis of randomized trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2012 DARE.

520. Effect of Aspirin on Vascular and Nonvascular Outcomes: Meta-analysis of Randomized Controlled Trials (Full text)

Effect of Aspirin on Vascular and Nonvascular Outcomes: Meta-analysis of Randomized Controlled Trials The net benefit of aspirin in prevention of CVD and nonvascular events remains unclear. Our objective was to assess the impact (and safety) of aspirin on vascular and nonvascular outcomes in primary prevention.MEDLINE, Cochrane Library of Clinical Trials (up to June 2011) and unpublished trial data from investigators.Nine randomized placebo-controlled trials with at least 1000 participants each (...) , reporting on cardiovascular disease (CVD), nonvascular outcomes, or death were included.Three authors abstracted data. Study-specific odds ratios (ORs) were combined using random-effects meta-analysis. Risks vs benefits were evaluated by comparing CVD risk reductions with increases in bleeding.During a mean (SD) follow-up of 6.0 (2.1) years involving over 100, 000 participants, aspirin treatment reduced total CVD events by 10% (OR, 0.90; 95% CI, 0.85-0.96; number needed to treat, 120), driven primarily

2012 EvidenceUpdates PubMed abstract